Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. 2018

Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, The Netherlands.

The replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record. However, pre-existing vector-specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing immunity. Nonetheless, orthopoxvirus-specific pre-existing immunity reduced the induction of antigen-specific antibodies under specific conditions and completely prevented induction of antigen-specific T cell responses by rMVA-based vaccination. Notably, antibodies induced by vaccinia virus vaccination, both in mice and humans, were not capable of neutralizing MVA. Thus, when using rMVA-based vaccines it is important to consider the main correlate of protection induced by the vaccine, the vaccine dose and the orthopoxvirus immune status of vaccine recipients.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females

Related Publications

Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
April 2009, Expert review of vaccines,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
January 2016, Expert review of vaccines,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
July 2009, Vaccine,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
September 2013, Vaccine,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
November 2014, Journal of virology,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
September 2022, Vaccines,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
March 2019, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
January 2007, The Journal of general virology,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
March 2017, Pathogens and global health,
Arwen F Altenburg, and Stella E van Trierum, and Erwin de Bruin, and Dennis de Meulder, and Carolien E van de Sandt, and Fiona R M van der Klis, and Ron A M Fouchier, and Marion P G Koopmans, and Guus F Rimmelzwaan, and Rory D de Vries
October 2017, Clinical and experimental immunology,
Copied contents to your clipboard!